Prognostic value of lymphovascular and perineural invasion in colorectal cancer: Lymphovascular and perineural invasion in colorectal cancer

Ertuğrul Gazi Alkurt; Bahadır Kartal; Mehmet Berksun Tutan; Azmi Lale; Erhan Aygen

doi:10.28982/josam.7561

Authors

Ertuğrul Gazi Alkurt Department of General Surgery, Hitit Erol Olçok Training and Research Hospital Hospital, Çorum, Turkey https://orcid.org/0000-0002-3044-5428
Bahadır Kartal Department of General Surgery, Hitit Erol Olçok Training and Research Hospital Hospital, Çorum, Turkey https://orcid.org/0000-0003-1647-9979
Mehmet Berksun Tutan Department of General Surgery, Hitit Erol Olçok Training and Research Hospital Hospital, Çorum, Turkey https://orcid.org/0000-0003-1834-7355
Azmi Lale Department of General Surgery, Fırat University Hospital, Elazığ, Turkey https://orcid.org/0000-0002-6559-2604
Erhan Aygen Department of General Surgery, Hitit Erol Olçok Training and Research Hospital Hospital, Çorum, Turkey https://orcid.org/0000-0003-4481-480X

DOI:

https://doi.org/10.28982/josam.7561

Keywords:

colorectal cancer, lymphovascular invasion, perineural invasion

Abstract

Background/Aim: Lymphovascular and perineural invasion (LVI and PNI, respectively) are associated with poor prognosis in various cancers. We sought to identify clinical variables associated with LVI and PNI in colorectal cancer (CRC) and their effects on survival.

Methods: Our study design is consistent with a retrospective cohort study. Data from 237 patients with documented LVI or PNI who underwent surgery for colorectal cancer between 2017 and 2021 were retrospectively reviewed. Demographic characteristics, surgery and pathology reports, disease-free and overall survival (DFS and OS, respectively) of the patients were examined.

Results: When the DFS duration of the patients were evaluated, The mean DFS of the LVI-negative group was 27.4 (15.09) months, and the mean of the LVI-positive patients was 20.45 (13) months. DFS was longer in the LVI-negative group (P<0.001). DFS was 52.26 (1.89) months in PNI-negative patients and 34.29 (2.71) months in PNI-positive patients. DFS expectation of PNI-positive patients was approximately 18 months less than that of negative patients (P<0.001). When the patients were evaluated in terms of OS duration, no significant difference was observed in LVI-negative and -positive patient groups, while the estimated OS duration was 52.29 (1.84) months in PNI-negative patients, and 40.10 (2.49) months in PNI-positive patients. OS was 12 months shorter in PNI-negative patients (P<0.001).

Conclusion: The use of PNI and LVI together was found to have a significant impact on the survival rates of patients with colorectal cancer. Documenting LVI and PNI status in biopsy specimens can aid in the management, prognosis, and decision-making for treating colorectal tumors.

Downloads

Download data is not yet available.

References

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. DOI: https://doi.org/10.3322/caac.21708

Guyot F, Faivre J, Manfredi S, Meny B, Bonithon-Kopp C, Bouvier A. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol. 2005;16(5):756-61. DOI: https://doi.org/10.1093/annonc/mdi151

Edge, Stephen B, Carolyn C. Compton. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-74. DOI: https://doi.org/10.1245/s10434-010-0985-4

McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79(2):191-203. DOI: https://doi.org/10.1038/sj.bjc.6690033

Schneider NI, Langner C. Prognostic stratification of colorectal cancer patients: current perspectives. Cancer Manag Res. 2014 Jul 2;6:291-300. DOI: https://doi.org/10.2147/CMAR.S38827

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Mar 2;19(3):329-59.

Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-305. DOI: https://doi.org/10.1016/j.annonc.2020.06.022

Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19. DOI: https://doi.org/10.1200/JCO.2004.05.063

Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;24(6):64–72. DOI: https://doi.org/10.1093/annonc/mdt354

Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(3):370–98. DOI: https://doi.org/10.6004/jnccn.2017.0036

Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO, Loconte NK, et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol. 2014 Jun;21(6):1781-91. DOI: https://doi.org/10.1245/s10434-014-3631-8

Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population. Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e29-e38. doi: 10.1016/j.clon.2016.09.001. Epub 2016 Sep 20. PMID: 27663601. DOI: https://doi.org/10.1016/j.clon.2016.09.001

Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jul;124(7):979-94. DOI: https://doi.org/10.5858/2000-124-0979-PFICC

Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, et al. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009; 27(31): 5131 DOI: https://doi.org/10.1200/JCO.2009.22.4949

Harris EI, Lewin DN, Wang HL, Lauwers GY, Srivastava A, Shyr Y, et al. Lymphovascular invasion in colorectal cancer: an interobserver variability study. Am J Surg Pathol.2008;32:1816–21. DOI: https://doi.org/10.1097/PAS.0b013e3181816083

Yuan H, Dong Q, Zheng B, Hu X, Xu JB, Tu S. Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017;8:46565–79. DOI: https://doi.org/10.18632/oncotarget.15425

Lim SB, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum.2010;53:377–84. DOI: https://doi.org/10.1007/DCR.0b013e3181cf8ae5

Beard CJ, Chen MH, Cote K. Loffredo M, Renshaw AA, Hurwitz M, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004;58:19–24. DOI: https://doi.org/10.1016/S0360-3016(03)01433-0

Harnden P, Shelley MD, Clements H, Coles B, Tyndale‐Biscoe RS, Naylor B, et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer-Am Cancer Soc. 2007;109:13–24. DOI: https://doi.org/10.1002/cncr.22388

Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Malyapa RS, Villaret, et al. Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol. 2007;30:93–96. DOI: https://doi.org/10.1097/01.coc.0000251224.16075.60

Peng J, Lu JJ, Zhu J, Xu Y, Lu H, Lian P, Cai G, Cai S. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer. Cancer J. 2008 Jan-Feb;14(1):54-61. doi: 10.1097/PPO.0b013e3181629a67. PMID: 18303484 DOI: https://doi.org/10.1097/PPO.0b013e3181629a67

Matsushima T, Mori M, Kido A, Adachi Y, Sugimachi K. Preoperative estimation of neural invasion in rectal carcinoma. Oncol Rep. 1998; 5(1):73-9. DOI: https://doi.org/10.3892/or.5.1.73

Knijn N, Mogk SC, Teerenstra S, Simmer F, Nagtegaal ID. Perineural Invasion is a Strong Prognostic Factor in Colorectal Cancer: A Systematic Review. Am J Surg Pathol. 2016 Jan;40(1):103-12. DOI: https://doi.org/10.1097/PAS.0000000000000518

Sun Q, Liu T, Liu P, Luo J, Zhang N, et al. Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery. J Cancer. 2019 May 21;10(10):2243-9. DOI: https://doi.org/10.7150/jca.31473

Hoda SA, Hoda RS, Merlin S, Shamonki J, Rivera M. Issues relating to lymphovascular invasion in breast carcinoma. Adv Anat Pathol. 2006;13:308–15. DOI: https://doi.org/10.1097/01.pap.0000213048.69564.26

Lim TY, Pavlidis P, Gulati S, Pirani T, Samaan M, Chung-Faye G, et al. Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. Inflamm Bowel Dis. 2016;22:39–40. DOI: https://doi.org/10.1097/MIB.0000000000000906

Huh JW, Lee JH, Kim HR, Kim YJ. Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg. 2013;206:758–763 DOI: https://doi.org/10.1016/j.amjsurg.2013.02.010

Zhong JW, Yang SX, Chen RP, Zhou YH, Ye MS, Miao L, et al. Prognostic Value of Lymphovascular Invasion in Patients with Stage III Colorectal Cancer: A Retrospective Study. Med Sci Monit. 2019;25:6043–50. DOI: https://doi.org/10.12659/MSM.918133

Yüksel C, Çulcu S, Gojayev A, Demirci S, Ünal A. E. Prognostic Value of Lymphovascular and Perineural Invasion in Colon Cancer. Acta Oncologica Turcica, 2021;54(2):166-74. DOI: https://doi.org/10.5505/aot.2021.23540

Sibio S, Di Giorgio A, D'Ugo S, Palmieri G, Cinelli L, Formica V, et al. Histotype influences emergency presentation and prognosis in colon cancer surgery. Langenbecks Arch Surg. 2019 Nov;404(7):841-51. DOI: https://doi.org/10.1007/s00423-019-01826-6

Nakamura Y, Hokuto D, Koyama F, Matsuo Y, Nomi T, Yoshikawa T, et al. The Prognosis and Recurrence Pattern of Right- and Left-Sided Colon Cancer in Stage II, Stage III, and Liver Metastasis After Curative Resection. Ann Coloproctol. 2021 Oct;37(5):326-36. DOI: https://doi.org/10.3393/ac.2020.09.14

Osterman E, Mezheyeuski A, Sjöblom T, Glimelius B. Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Ann Surg Oncol. 2020 Apr;27(4):1036-45. DOI: https://doi.org/10.1245/s10434-019-08148-3

Zhang C, Yin S, Tan Y, Huang J, Wang P, Hou W, et al. Patient Selection for Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer: A Systematic Review and Meta-Analysis. Am J Clin Oncol. 2020 Apr;43(4):279-87. DOI: https://doi.org/10.1097/COC.0000000000000663